United States v. Chin

965 F.3d 41
CourtCourt of Appeals for the First Circuit
DecidedJuly 9, 2020
Docket18-1263P
StatusPublished
Cited by10 cases

This text of 965 F.3d 41 (United States v. Chin) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Chin, 965 F.3d 41 (1st Cir. 2020).

Opinion

United States Court of Appeals For the First Circuit

Nos. 18-1263, 18-1310, 18-1500

UNITED STATES OF AMERICA,

Appellee, Cross-Appellant,

v.

GLENN A. CHIN,

Defendant, Appellant, Cross-Appellee.

APPEALS FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

[Hon. Richard G. Stearns, U.S. District Judge]

Before

Barron, Stahl, and Lipez, Circuit Judges.

James L. Sultan, with whom Kerry A. Haberlin and Rankin & Sultan were on brief, for appellant/cross-appellee. David M. Lieberman, Attorney, Criminal Division, Appellate Section, United States Department of Justice, with whom Andrew E. Lelling, United States Attorney, Amanda P. Strachan, Assistant United States Attorney, George P. Varghese, Assistant United States Attorney, Brian A. Benczkowski, Assistant Attorney General, and Matthew S. Miner, Deputy Assistant Attorney General, were on brief, for appellee/cross-appellant. July 9, 2020 BARRON, Circuit Judge. These consolidated appeals, like

those we also decide today in United States v. Cadden, ___ F.3d

___ (1st Cir. 2020) [Nos. 17-1694, 17-1712, 17-2062], concern

convictions that stem from a 2012 scandal involving the

Massachusetts-based New England Compounding Center ("NECC"). The

scandal broke after federal investigators traced the cause of a

deadly nationwide outbreak of fungal meningitis and other

illnesses to medications that NECC had produced at its facilities.

Federal criminal charges were then brought against a number of

NECC employees, including the defendant in this case, Glenn Chin,

who was NECC's supervising pharmacist at the time. For his role

in the scandal, he was convicted in 2017 of numerous federal

crimes, and, in consequence, sentenced to a lengthy term of

imprisonment, subjected to an order of forfeiture, and ordered to

pay restitution.

Chin now challenges two of those convictions, for

racketeering and racketeering conspiracy, respectively. He

contends that they must be reversed because the evidence did not

suffice to support them. He also contends that, in consequence,

his prison sentence must be vacated. If he is right about the

lack of evidence to support his convictions, then the order of

forfeiture also must be reversed.

The government, for its part, brings its own appeal. It

challenges the prison sentence that Chin received as well as both

- 3 - the $175,000 order of forfeiture that the District Court imposed

on him and its award of restitution of an as-yet-unspecified

amount.

We affirm both of Chin's federal racketeering-related

convictions. However, we vacate and remand the prison sentence,

the forfeiture order, and the restitution order.

I.

Our opinion in Cadden addresses the consolidated appeals

in the criminal case against Chin's boss and alleged co-conspirator

at NECC, Barry Cadden. He was charged in the same indictment as

Chin but his trial on those charges was severed from Chin's. See

Cadden, ___ F.3d at ___ [slip op. at 7-8]. The issues that we

confront here overlap in many respects with those that we address

in our opinion in Cadden's case. We thus refer to our reasoning

there throughout the analysis that follows. We also refer the

reader to that opinion for additional details about NECC's

practices and the federal criminal investigation into them.

Briefly stated, however, the facts relevant to the appeals in

Chin's case are the following.

The practice of compounding involves combining drugs

with other substances to produce medications. As a compounding

pharmacy, NECC -- which was based in Framingham, Massachusetts --

prepared specialized medications, otherwise unavailable in the

- 4 - wider market, to hospitals and other medical providers upon their

request.

Chin was a trained pharmacist who served as a supervisor

at both of NECC's clean rooms. The company's compounding

operations that produced the medications tied to the outbreak took

place in one of these clean rooms.

On December 16, 2014, following an extensive federal

criminal investigation into NECC's role in the outbreak, Chin was

charged, along with Cadden and twelve other individuals affiliated

with NECC, in a 131-count indictment in the United States District

Court for the District of Massachusetts. The indictment charged

Chin with racketeering in violation of 18 U.S.C. § 1962(c);

racketeering conspiracy in violation of 18 U.S.C. § 1962(d);

forty-three counts of federal mail fraud in violation of 18 U.S.C.

§ 1341; and thirty-two counts of violating the Federal Food, Drug,

and Cosmetic Act ("FDCA"), see 21 U.S.C. §§ 331(a), 333(a).

The racketeering charge alleged sixty-eight predicate

acts of racketeering to support the allegation that Chin

participated in the conduct of NECC through a "pattern of

racketeering activity." See 18 U.S.C. § 1962(c). These alleged

predicate acts of racketeering included forty-three that were

premised on mail fraud allegations, as mail fraud is a racketeering

activity. See id. § 1961(1)(B). These allegations corresponded

- 5 - to the mail fraud allegations set forth in forty-three of the

stand-alone mail fraud counts.

The alleged mail fraud entailed NECC misrepresenting its

various safety protocols to customers who purchased its

medications. Those medications included the contaminated "high-

risk" sterile medication, methylprednisolone acetate ("MPA"),

that NECC had compounded during Chin's tenure as the supervising

pharmacist there and that had given rise to the outbreak. In

particular, NECC was alleged to have misrepresented that it had

complied with the safety standards set forth in Chapter 797 of the

United States Pharmacopeia ("USP-797"), which applies to high-risk

sterile compounded medications, including MPA.

The sixty-eight alleged predicate acts of racketeering

also included twenty-five that were premised on allegations of

second-degree murder, which is itself a racketeering activity.

See id. § 1961(1)(A). The allegations of second-degree murder

were tied to twenty-five patients who had died from having been

injected with the contaminated MPA that NECC had compounded.

The racketeering conspiracy charge did not identify

specific predicate acts of racketeering that it alleged that Chin

conspired to commit. See id. § 1962(d). Rather, the indictment

alleged that Chin conspired to commit a racketeering violation

through a pattern of racketeering activity that involved only

unspecified instances of mail fraud.

- 6 - The District Court severed Chin's case from Cadden's and

the other defendants'. Chin's case proceeded to trial, and the

jury found him guilty on all counts. A special verdict form

indicated that, for the purposes of the racketeering offense, the

jury found that the government had proved twelve of the sixty-

eight alleged predicate acts of racketeering, each of which

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Miranda-Montanez
73 F.4th 24 (First Circuit, 2023)
United States v. Cardozo
68 F.4th 725 (First Circuit, 2023)
United States v. Cadden
51 F.4th 32 (First Circuit, 2022)
United States v. Chin
41 F.4th 16 (First Circuit, 2022)
United States v. Thomas
15 F.4th 536 (First Circuit, 2021)
United States v. Conigliaro
15 F.4th 26 (First Circuit, 2021)
United States v. Solis-Vasquez
10 F.4th 59 (First Circuit, 2021)
United States v. Svirskiy
989 F.3d 88 (First Circuit, 2021)
In Re: Akebia Therapeutics v.
981 F.3d 32 (First Circuit, 2020)

Cite This Page — Counsel Stack

Bluebook (online)
965 F.3d 41, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-chin-ca1-2020.